Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04823299
Other study ID # v21022021
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date July 2024
Est. completion date September 2026

Study information

Verified date March 2024
Source Ottawa Heart Institute Research Corporation
Contact Girish Nair, MD
Phone 613-696-7272
Email GNair@ottawaheart.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Atrial Fibrillation (AF) is a heart rhythm disturbance that affects over a million people in North America. AF can cause strokes, heart failure, poor quality of life and may lead to premature death. Catheter ablation has been shown to be superior to medications for symptoms, prevention of stroke and heart failure. AF recurrence is a problem after catheter ablation. Our research has found that in most cases AF recurrence occurs because the catheter procedure was ineffective. The objective of our clinical trial is to find out if a new method of performing the catheter procedure will be more effective in preventing AF recurrence compared to the current standard of care ablation procedure. Subjects will be randomly allocated to undergo either the standard of care ablation, or the novel patient tailored ablation. The novel method aims to understand the unique factors responsible for AF in each individual and uses this information to perform a patient-tailored catheter ablation procedure. This is expected to improve the results of AF ablation. The effectiveness and safety of the ablation procedure will be specifically evaluated in women to understand the effect of sex on AF ablation.


Description:

Catheter ablation (CA) for paroxysmal atrial fibrillation (AF) is beset by the significant limitation of recurrent AF in one third of subjects. Subjects with recurrence of AF usually require repeat ablation procedures with the attendant risk of potentially serious complications and significant costs to the health care system. We hypothesize that an innovative, a patient specific precise CA strategy will significantly reduce AF recurrence. This study will determine whether a precise, patient specific ablation strategy (tailored to the patient's triggers and substrate) combining electrophysiological (EPS) testing guided radiofrequency catheter ablation (RFA) for pulmonary vein isolation (PVI) using the wide-area circumferential (WACA) technique along with non-pulmonary vein trigger (NPVT) and low-voltage area (LVA) ablation will improve freedom from recurrent atrial fibrillation (AF) when compared to PVI alone strategy using cryoballoon ablation (CAB). The PVI-WACA technique has a 'ceiling effect' due to PV reconnection, especially along the posterior wall of the LA as shown in an observational study investigating the pattern of PV reconnection from our institution. Further attempts at improving durable PVI rates with higher energy ablation may not be possible due to concerns regarding esophageal injury and development of atrio-esophageal fistula. It may be possible to improve the results of CA for paroxysmal AF by targeting NPVT and LVA that are not usually targeted during CA using the PVI-WACA only strategy. This trial is a single-blinded (subjects blinded), prospective, parallel arm RCT. Subjects satisfying the inclusion and exclusion criteria will be randomized (1:1) to either the control arm (cryoballoon ablation) or the experimental arm (RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation). Randomization will be conducted after informed consent has been obtained and before catheter ablation. The first 60 days after catheter ablation will be considered a "blanking-period" and atrial tachyarrhythmias (AF, Atrial Flutter [AFl] or Atrial Tachycardia [AT]) occurring during this period will be documented. However, these will not be considered treatment failures. Subject accrual will occur over a 36-month period and each subject will have a minimum follow-up period of 24 months, with a total trial duration of 60-months. Subjects will be followed up at 2,6,12,18 and 24 months after ablation, with an implantable loop recorder (ILR) interrogation. Quality of life questionnaires (EQ-5D, AFEQT questionnaires and CCS-SAF scale) will be administered at baseline,12-months and 24 months post ablation visit. A tool to assist in decision making will be administered to subjects during the consent process.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 390
Est. completion date September 2026
Est. primary completion date September 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years on the date of consent for the trial. 2. Subjects must have Paroxysmal AF with at least two episodes of AF over the past 12 months; Early Persistent AF- at least two episodes of AF. 3. At least one episode of AF documented on 12-lead ECG, Holter monitor, Trans- telephonic monitor (TTM) or Loop Recorder. 4. Subjects must be able to provide informed consent. Exclusion Criteria: 1. Persistent and permanent AF 2. History of previous catheter or surgical ablation for AF, AFl, AT, AVNRT, AVRT. 3. Documented AVNRT, AVRT, AT or Atrial Flutter prior to enrolment in the trial. 4. Previous left atrial (LA) ablation or LA surgery. 5. Previous pulmonary vein stenosis or pulmonary vein stent. 6. Pre-existing hemi-diaphragmatic paralysis. 7. Active intracardiac thrombus. 8. Contraindication to systemic oral anticoagulation therapy or radiocontrast materials. 9. Current immunosuppressant therapy (corticosteroids, biologic immunomodulators; such patients may be considered if they can safely discontinue immunosuppressants for three months prior to and for three months following catheter ablation). 10. Reversible causes of AF (eg. uncontrolled hyperthyroidism, within six months of cardiac surgery). 11. Left ventricular ejection fraction <35%. 12. NYHA Class 3-4 heart failure. 13. Hypertrophic cardiomyopathy with septal or posterior LV wall thickness of >1.8 cm. 14. Significant valve disease (moderate or severe mitral/aortic stenosis or regurgitation). 15. Known adverse reaction to adenosine. 16. Significant chronic kidney disease (eGFR <30ml/min/1.73m2). 17. Significant congenital heart disease (including atrial septal defects or pulmonary vein abnormalities; however, subjects with patent foramen ovale will not be excluded). 18. Pregnant subjects. 19. Cerebral ischemic event (stroke or transient ischemic attack) in the six months prior to consenting for the trial. 20. Life expectancy less than one-year. 21. Currently participating or anticipated to participate in clinical trials of drug, device or biologic agents that could affect the results of this trial. 22. Unwilling or unable to comply fully with study procedures and follow-up.

Study Design


Intervention

Procedure:
Cryoballoon ablation
Cryoballoon pulmonary vein isolation ablation
Radiofrequency catheter ablation +EPS guided trigger and substrate ablation
RF based WACA ± electrophysiological testing guided ablation of non-PV triggers of AF and low voltage area ablation

Locations

Country Name City State
Canada McGill University Health Center Montreal Quebec
Canada University of Ottawa Heart Institute Ottawa Ontario

Sponsors (3)

Lead Sponsor Collaborator
Ottawa Heart Institute Research Corporation McGill University, University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Freedom from atrial fibrillation, atrial flutter or atrial tachycardia AF, AFl or AT, symptomatic or asymptomatic lasting = 30 seconds 61 to 365 days after ablation
Secondary Atrial fibrillation burden Total duration of AF recorded on ambulatory monitoring/total duration of monitoring 760 days
Secondary Long-term rate of documented AF, AFl or AT Long-term rate of documented AF, AFl or AT lasting = 30 seconds 760 days
Secondary Incidence of any ECG/ILR documented AF, AFl or AT Incidence of any ECG/ILR documented AF, AFl or AT (symptomatic or asymptomatic; lasting = 30 seconds First 60 days after catheter ablation
Secondary Ablation procedure duration Catheter ablation procedure time On day of ablation
Secondary Fluoroscopic exposure Total Air Kerma (mGy) On day of ablation
Secondary Fluoroscopic exposure dose Dose Area Protocol (Gy.cm2) On day of ablation
Secondary Procedure Related Complications Stroke, PV stenosis, pericarditis, phrenic nerve palsy, cardiac perforation, atrio-esophageal fistula, major bleeding and/or death. 760 days
Secondary Emergency room visits or hospitalization due to recurrent AF, AFl or AT Emergency room visits or hospitalization due to recurrent AF, AFl or AT 760 days
Secondary Repeat catheter ablation for AF, AFl or AT Repeat catheter ablation for AF, AFl or AT 760 days
Secondary Quality of life scale EQ-5D 12 and 24 months
Secondary Quality of life questionnaire AFEQT questionnaire 12 and 24 months
Secondary Quality of life SAF scale CCS-SAF scale 12 and 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A